We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | TG:TEV | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -0.15 | -0.99% | 15.05 | 14.90 | 15.15 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 15.35 | 14.90 | 15.15 | 5,777 | 20:32:11 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/3/2025 | 21:30 | UKREG | Teva to Present at Barclays Global Healthcare Conference and Leerink.. |
| 27/2/2025 | 13:00 | UKREG | 2025 Community Routes: Access to Mental Health Care Grants Awarded to.. |
| 25/2/2025 | 21:00 | UKREG | Teva and Medincell Announce FDA Acceptance of Supplemental New Drug.. |
| 22/2/2025 | 07:20 | UKREG | Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025.. |
| 21/2/2025 | 12:54 | UKREG | Les besoins du patient au centre de toutes les priorités : pourquoi.. |
| 21/2/2025 | 12:54 | UKREG | Der Patient steht an erster Stelle: Warum Europa handeln muss, um den.. |
| 21/2/2025 | 11:00 | UKREG | Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now.. |
| 18/2/2025 | 21:30 | UKREG | Teva to Host Conference Call on February 24, 2025 to Discuss New Data.. |
| 18/2/2025 | 11:00 | UKREG | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License.. |
| 29/1/2025 | 12:00 | UKREG | Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial.. |
1 Year Teva Pharmaceutical Indu... Chart |
Intraday Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
